Oncologic outcomes of de-escalating axillary treatment in clinically node-positive breast cancer patients treated with neoadjuvant systemic therapy - A two center cohort study.

Background: The aim of the present study was to report the 5-year axillary recurrence-free interval (aRFI) in clinically node-positive breast cancer patients treated according to a de-escalating axillary treatment protocol after neoadjuvant systemic therapy (NST).

Methods: All patients diagnosed in two hospitals between October 2014 and March 2021 were identified retrospectively. Data on diagnostic workup, treatment and follow-up was collected.

EZH2 is a key component of hepatoblastoma tumor cell growth.

Background: Enhancer of zeste homolog 2 (EZH2) catalyzes the trimethylation of histone H3 at lysine 27 via the polycomb recessive complex 2 (PRC2) and plays a time-specific role in normal fetal liver development. EZH2 is overexpressed in hepatoblastoma (HB), an embryonal tumor. EZH2 can also promote tumorigenesis via a noncanonical, PRC2-independent mechanism via proto-oncogenic, direct protein interaction, including β-catenin.

Liver Transplantation for Colorectal Liver Metastases.

Colorectal cancer is one of the most common malignancies worldwide. Approximately half of the patients diagnosed will develop colorectal liver metastases (CRLM). Liver resection has a 50% 5-year survival; however, only a fourth of cases are resectable.

Optimizing Catalytic Depolymerization of Lignin in Ethanol with a Day-Clustered Box-Behnken Design.

Lignin is a potential resource for biobased aromatics with applications in the field of fuel additives, resins, and bioplastics. Via a catalytic depolymerization process using supercritical ethanol and a mixed metal oxide catalyst (CuMgAlO), lignin can be converted into a lignin oil, containing phenolic monomers that are intermediates to the mentioned applications. Herein, we evaluated the viability of this lignin conversion technology through a stage-gate scale-up methodology.